The Saint Petersburg International Mercantile Exchange was established in May 2008 on the initiative of President and the Government of the Russian Federation.
The main markets in which it operates include: Refined Products, Crude Oil, Natural Gas, Timber, Mineral Fertilizers, Metals, etc. The Exchange is an effective channel for selling and buying real commodities at the market price. The Exchange’s derivatives market offers trading in cash settled futures for price indices of exchange-traded refined products and physically settled futures for refined products.
The generated price indices of the Exchange are used to monitor tariff, transfer pricing, and government procurement.
All major manufacturers and their distribution companies provide SPIMEX with information on OTC contracts made.
SPX Information and Analytics Platform is the largest Russian source of statistical and pricing data on commodity markets. The platform aggregates information from various sources, normalizes it, and delivers in convenient and modern formats.
Sistema PJSFC is a publicly traded diversified Russian holding company in the sectors of telecommunications and digital services, IT and high technologies, e-commerce, paper and packaging, agriculture, construction and real estate, medical and pharmacy services, hospitality and others. The corporation was founded in 1993. Revenue in 2023 was RUB 1231,6 billion; total assets equaled RUB 2,8 trillion as of 31 December 2024. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange.
The modern, dynamically developing Russian pharmaceutical company, one of the leaders in the pharmaceutical industry of the Russian Federation in terms of growth rates.
Skopinpharm is a developer and manufacturer of medicines, one of the leading suppliers under the program of 14 high-cost nosologies in accordance with the Ministry of Health of the Russian Federation orders. Skopinpharm offers a range of medications under the regional preferential insurance program, and is also one of the main suppliers of the Circle of Good Foundation for helping children with serious and life-threatening illnesses. The company's turnover amounted to more than 44.1 billion rubles by 2024.
The company operates in the following key areas: manufacture of plasma-derived medicinal products, cytostatics, and medicinal products used for the treatment of various oncological diseases. As part of developing these business areas, the company has constructed new manufacturing and storage buildings, performs technology transfer of unique pharmaceutical manufacturing processes, and has built a plasma storage facility with a laboratory unit, which will ensure proper storage of plasma intended for fractionation (raw materials for the manufacture of human plasma-derived medicinal products).
At the same time, in partnership with health authorities, a modern system for the procurement of blood plasma is being created and a voluntary donation program is being developed.
Skopinpharm actively supports the training and advanced training of pharmaceutical industry specialists and is one of the founders of the Academy of Good Practices of the EAEU.
